People with certain health conditions, including a history of pancreatitis, diabetic retinopathy (vision loss or changes in people with type 2 diabetes), or kidney or gallbladder problems, may require extra monitoring while taking semaglutide to ensure the medication remains safe for them to use
That number comes from large clinical trials of Wegovy, where people taking 2.4 mg of semaglutide weekly lost an average of 15% of their starting weight over 68 weeks
[23] Most practitioners find that weekly injections help maintain consistent levels of the lipotropic factors
You'll typically start with a 2.5mg dose and increase it every four weeks (or as advised by our clinicians) until you reach your target dose of 5mg, 10mg, or 15mg
For tirzepatide reconstitution , the process is equally critical
No standardized clinical trials exist